Previously, we reported that GPC3-targeted CAR-T cells developed by our laboratory were well tolerated in the phase I clinical trial for HCC patients (NCT02395250) (37, 38), indicating that GPC3 is a relatively safe target. The gene discussed is GPC3; the disease is hepatocellular carcinoma.